Created with an expert scientific advisory board, Pain Therapeutics 2017 will hone in on the latest innovations and novel approaches to pain therapy and analgesic drugs as well as look at the practicalities of using animal models and translational biomarkers in pain research.
Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, presentations from a selection of hand-picked pharmaceutical companies currently developing novel treatments in pain, will keep attendees at the forefront of medical breakthroughs to adapt to the growing need towards minimising opioid dependency and new drug discovery.
Exclusive new findings from phase II clinical trials will be just some of the highlights at the 17th annual show when it returns to London this spring.
KEYNOTE SPEAKERS INCLUDE
• Anthony Jones, Prof of Neuro-Rheumatology, University of Manchester
• Dr Steven Kamerling, Therapeutic Area Head for Pain, Inflammation & Oncology, Zoetis
• Dr Joseph W. Stauffer, CMO, Cara Therapeutics
• Dr Stephen Doberstein, Senior VP & CSO, Nektar Pharmaceuticals
• Dr Iain Chessell, Head of Neuroscience, AstraZeneca
• Dr Randall Stevens, CMO, Centrexion Therapeutics
• Dr Richard Butt, CEO, Apollo Therapeutics
• Prof Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutica
• Dr Narender Gavva, Scientific Director, Amgen
• Dr Thomas Christoph, Head of Pharmacology & Biomarker Development, Grunenthal
• Dr Ian Bell, Principal Scientist, MSD, USA
The agenda also features talks from Lilly UK, Novartis, Mundipharma + more!
REASONS TO ATTEND IN 2017
• New guideline on the clinical development of pain medicine
• Strategies to minimise risk of opioid dependence
• Evaluate the translation gap with case studies from a pre-clinical and clinical perspective
• Examine the use of animal models to study pain pathways
• Big Pharma updates on Neuropathic pain
Earlybird savings online
Price
Conference + 1 Workshop: GBP 2098
Conference: GBP 1499
Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, presentations from a selection of hand-picked pharmaceutical companies currently developing novel treatments in pain, will keep attendees at the forefront of medical breakthroughs to adapt to the growing need towards minimising opioid dependency and new drug discovery.
Exclusive new findings from phase II clinical trials will be just some of the highlights at the 17th annual show when it returns to London this spring.
KEYNOTE SPEAKERS INCLUDE
• Anthony Jones, Prof of Neuro-Rheumatology, University of Manchester
• Dr Steven Kamerling, Therapeutic Area Head for Pain, Inflammation & Oncology, Zoetis
• Dr Joseph W. Stauffer, CMO, Cara Therapeutics
• Dr Stephen Doberstein, Senior VP & CSO, Nektar Pharmaceuticals
• Dr Iain Chessell, Head of Neuroscience, AstraZeneca
• Dr Randall Stevens, CMO, Centrexion Therapeutics
• Dr Richard Butt, CEO, Apollo Therapeutics
• Prof Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutica
• Dr Narender Gavva, Scientific Director, Amgen
• Dr Thomas Christoph, Head of Pharmacology & Biomarker Development, Grunenthal
• Dr Ian Bell, Principal Scientist, MSD, USA
The agenda also features talks from Lilly UK, Novartis, Mundipharma + more!
REASONS TO ATTEND IN 2017
• New guideline on the clinical development of pain medicine
• Strategies to minimise risk of opioid dependence
• Evaluate the translation gap with case studies from a pre-clinical and clinical perspective
• Examine the use of animal models to study pain pathways
• Big Pharma updates on Neuropathic pain
Earlybird savings online
Price
Conference + 1 Workshop: GBP 2098
Conference: GBP 1499
